B
Billy Lin
Researcher at National Institutes of Health
Publications - 7
Citations - 274
Billy Lin is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Hepatitis C virus & Hepatitis C. The author has an hindex of 6, co-authored 7 publications receiving 225 citations. Previous affiliations of Billy Lin include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection
Shanshan He,Billy Lin,Virginia Chu,Zongyi Hu,Xin Hu,Jingbo Xiao,Amy Wang,Cameron J. Schweitzer,Qisheng Li,Michio Imamura,Nobuhiko Hiraga,Noel Southall,Marc Ferrer,Wei Zheng,Kazuaki Chayama,Juan J. Marugan,T. Jake Liang +16 more
TL;DR: Chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, is identified and characterized as an anti-HCV drug in vitro and in vivo, and represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.
Journal ArticleDOI
Mitochondrial Ca(2+) uptake by the voltage-dependent anion channel 2 regulates cardiac rhythmicity.
Hirohito Shimizu,Johann Schredelseker,Jie Huang,Kui Lu,Shamim Naghdi,Fei Lu,Sarah Franklin,Hannah D. G. Fiji,Kevin Wang,Huanqi Zhu,Cheng Tian,Billy Lin,Haruko Nakano,Amy Ehrlich,Junichi Nakai,Adam Z. Stieg,James K. Gimzewski,Atsushi Nakano,Joshua I. Goldhaber,Thomas M. Vondriska,György Hajnóczky,Ohyun Kwon,Jau-Nian Chen +22 more
TL;DR: A critical modulatory role for VDAC2-dependent mitochondrial Ca2+ uptake in the regulation of cardiac rhythmicity is demonstrated and efsevin is identified based on its potent activity to restore coordinated contractions in tremblor.
Journal ArticleDOI
Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection
Shanshan He,Jingbo Xiao,Andrés E. Dulcey,Billy Lin,Adam Rolt,Zongyi Hu,Xin Hu,Amy Wang,Xin Xu,Noel Southall,Marc Ferrer,Wei Zheng,T. Jake Liang,Juan J. Marugan +13 more
TL;DR: Struct–activity relationship (SAR) efforts that resulted in the optimization of novel chlorcyclizine derivatives as anti-HCV agents can serve as lead preclinical candidates for the treatment of hepatitis C virus infection and as probes to study hepatitis Cirus pathogenesis and host–virus interaction.
Journal ArticleDOI
High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors.
Shanshan He,Prashi Jain,Billy Lin,Marc Ferrer,Zongyi Hu,Noel Southall,Xin Hu,Wei Zheng,Benjamin Neuenswander,Chul Hee Cho,Yu Chen,Shilpa A. Worlikar,Jeffrey Aubé,Richard C. Larock,Frank J. Schoenen,Juan J. Marugan,T. Jake Liang,Kevin J. Frankowski +17 more
TL;DR: The optimization of the benzofuran scaffold led to the identification of several exemplars with potent inhibition of HCV, low cytotoxicity, and excellent selectivity, and the design and synthesis of a 45-compound library to comprehensively explore the anti-HCV activity.
Journal ArticleDOI
Evaluation of antiviral drug synergy in an infectious HCV system.
TL;DR: The results show that in vitro combination studies of anti-HCV DAAs in the HCVcc system may provide useful guidance for drug combination designs in clinical studies and demonstrate that these DAA classes in combination with host-targeting agents or entry inhibitors may improve HCV treatment response.